Вернуться к статье
Морфология зоны имплантации синтетических герниопротезов, модифицированных углеродом
Table 1 - Study group "Esfil-light," Subgroups with Coating and without Coating
| Groups | Observation periods | Reliability of differences | ||
Day 7 | Day 14 | 180th day | |||
Infiltrate thickness, µm | Control | 125±25 | - | - | P1*=0.04 P2*>>0.05 P3*>>0.05 |
With coating | 90±10 | - | - | ||
Polymorphonuclear leukocytes,% | Control | 47±3 | 25±4 | - | P1*=0.1 P2*=0.04 P3*>>0.05 |
With coating | 42±3 | 17±3 | - | ||
Small lymphocyte type cells,% | Control | 20±2 | 15 ± 2 | - | P1*=0.1 P2*=0.04 P3*<<0.01 |
With coating | 17 ± 2 | 10 ± 1 | 7±1 | ||
Histiocytes,% | Control | 26±2 | 27±2 | 35 ± 3 | P1*=0.08 P2*=0.02 P3*=0.004 |
With coating | 22±2 | 17 ± 2 | 10 ± 2 | ||
Foreign body giant multinucleated cells (FBGCs) | Control | 7±1 | 9±1 | - | P1*<<0.01 P2*<<0.01 P3*<<0.01 |
With coating | - | - | - | ||
Capsule thickness, µm | Control | - | 175±35 | 70±10 | P1*>>0.05 P2*=0.05 P3*=0.03 |
With coating | - | 130±10 | 52±5 | ||
